Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director · CEO and President | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 2,072,890 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Sale · Disposed 22,408 · Balance 2,072,890 F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025. F2: This transaction was executed in multiple trades at prices ranging from $3.485 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $3.485 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 21:55 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 22,408 | $3.52 | $78,822.38 |
DisclosureSEC source: 0001601830-26-000105 · wk-form4_1789077354.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,072,890 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.485 to $3.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 21:44 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 80,498 | $3.16 | $254,373.68 |
DisclosureSEC source: 0002020969-26-000006 · wk-form4_1787089472.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,095,298 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:02 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 23,588 | $3.58 | $84,459.19 |
DisclosureSEC source: 0002020969-26-000004 · wk-form4_1780693375.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,175,796 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.56 to $3.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:54 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 62,701 | $3.04 | $190,611.04 |
DisclosureSEC source: 0002020969-26-000002 · wk-form4_1779227687.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,199,384 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 28,298 | $3.35 | $94,659.64 |
DisclosureSEC source: 0001601830-26-000048 · wk-form4_1773265272.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,262,085 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025 F2 · price: This transaction was executed in multiple trades at prices ranging from $3.32 to $3.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 00:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 14,280 | $3.49 | $49,837.20 |
DisclosureSEC source: 0001601830-26-000019 · wk-form4_1771547436.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,290,383 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 10,364 | $3.98 | $41,248.72 |
DisclosureSEC source: 0001601830-26-000014 · wk-form4_1770765506.xml · nonDerivative · entry 3 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,304,663 F3 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 30,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000014 · wk-form4_1770765506.xml · nonDerivative · entry 2 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,315,027 F2 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,673,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000014 · wk-form4_1770765506.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,284,681 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2026 and every three months thereafter. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 22:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 124,403 | $4.41 | $548,592.35 |
DisclosureSEC source: 0001601830-25-000176 · wk-form4_1767047073.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 611,135 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.30 to $4.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 00:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 17,584 | $4.14 | $72,797.76 |
DisclosureSEC source: 0002020969-25-000006 · wk-form4_1763599049.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,538 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 169,851 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0002020969-25-000004 · wk-form4_1762464230.xml · derivative · entry 2 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,851 Underlying: Class A Common Stock · 169,851 shares Expires 2035-11-05 F2 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on December 5, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 84,925 | $0.00 | $0.00 |
DisclosureSEC source: 0002020969-25-000004 · wk-form4_1762464230.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 753,122 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on February 15, 2026, and every three months thereafter. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 22:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 36,599 | $5.52 | $202,172.88 |
DisclosureSEC source: 0001601830-25-000131 · wk-form4_1755642116.xml · nonDerivative · entry 2 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,197 F2 · kind: Represents shares that have been required to be sold by the Issuer to satisfy the tax withholding and remittance obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 22:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 3,789 | $5.64 | $21,369.96 |
DisclosureSEC source: 0001601830-25-000131 · wk-form4_1755642116.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704,796 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:44 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 3,796 | $4.25 | $16,133.00 |
DisclosureSEC source: 0001601830-25-000084 · wk-form4_1747687456.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 708,585 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 420,226 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001628280-25-004086 · wk-form4_1738792220.xml · derivative · entry 4 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,226 Underlying: Class A Common Stock · 420,226 shares Expires 2035-02-03 F4 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 2,753 | $7.25 | $19,959.25 |
DisclosureSEC source: 0001628280-25-004086 · wk-form4_1738792220.xml · nonDerivative · entry 3 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,381 F3 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 8,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004086 · wk-form4_1738792220.xml · nonDerivative · entry 2 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715,134 F2 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 210,113 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004086 · wk-form4_1738792220.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,085 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2025 and every three months thereafter. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 21:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 993,944 | $0.00 Strike: $7.34 | $0.00 |
DisclosureSEC source: 0001601830-24-000106 · wk-form4_1722892337.xml · derivative · entry 2 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 993,944 Underlying: Class A Common Stock · 993,944 shares Expires 2034-08-01 F2 · derivative.exercise_date: This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 21:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 496,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000106 · wk-form4_1722892337.xml · nonDerivative · entry 1 Khan Najat · CIK 0002020969 · Director · Chief R&D Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 496,972 F1 · kind: This RSU vests as to one fourth (1/4th) of the units subject to the RSU on August 15, 2025 and one sixteenth (1/16th) every three months thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.